Anne Luetkemeyer is an Infectious Disease physician affiliated with San Francisco General Hospital. OpenAlex indexes 119 publications with 7,031 citations (h-index 32); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
995 Potrero Ave
Box 0874
San Francisco, CA 941102859
Telephone
415-476-4082Registry record last updated 13 Jan 2012.
Clinical trials
- Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
Sponsor: University of California, San Francisco
- A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
Sponsor: University of California, San Francisco
- Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Shionogi IncProgram year20252 payments
- ViiV Healthcare CompanyProgram year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios
University of California, San Francisco
FY2026$1,480,679R01AI181732 - The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios
University of California, San Francisco
FY2025$1,493,206R01AI181732 - The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios
University of California, San Francisco
FY2024$1,628,180R01AI181732
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends
JAMA Internal Medicine
2025 - Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
Clinical Infectious Diseases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Geoffrey Manley, MD, PhD
San Francisco General Hospital
Melvin Cheitlin, MD
San Francisco General Hospital
John Yue, MD
San Francisco General Hospital
Bryan Greenhouse, MD
San Francisco General Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”